Adversarial Injection · Dostarlimab (Jemperli; TSR-042; CAS 2028975-95-9; MW ~148,500 Da; IgG4 kappa humanized monoclonal antibody anti-PD-1 [FOURTH PD-1 INHIBITOR in Glyphward 626-attack portfolio — FOURTH ANTI-PD-1 (PROGRAMMED DEATH-1) ANTIBODY EVER FDA APPROVED (BLA 761174 April 22 2021; after pembrolizumab September 2014, nivolumab December 2014, cemiplimab September 2018); FIRST PD-1 INHIBITOR SPECIFICALLY APPROVED FOR dMMR (mismatch repair deficient) ENDOMETRIAL CANCER (endometrial cancer [EC] is the most common gynecologic cancer in the US; dMMR/MSI-H EC [~25-30% of all EC] has the highest tumor mutation burden of any solid tumor and is uniquely sensitive to checkpoint blockade; pembrolizumab had broad dMMR approval but dostarlimab's BLA 761174 was the first approval specifically focused on dMMR EC; RUBY/ENGOT-EN6 first-line dMMR EC: dostarlimab + carboplatin/paclitaxel → PFS HR 0.28 [not reached vs 7.7 months; 2-year PFS 61.4% vs 15.7%] and OS HR 0.32 — landmark first-line dMMR EC data; standard approval August 4 2023; LANDMARK 100% COMPLETE RESPONSE IN RECTAL CANCER: NeoTTT pilot (Cercek et al. NEJM June 23 2022; 10.1056/NEJMoa2201445): dostarlimab-gxly neoadjuvant single-agent in dMMR locally advanced rectal cancer; n=12 patients treated with dostarlimab 500 mg q3w × 6 months; ALL 12 PATIENTS ACHIEVED COMPLETE CLINICAL RESPONSE (100% cCR) — meaning no residual tumor detectable by endoscopy, MRI, PET, or biopsy; ALL 12 PATIENTS AVOIDED SURGERY AND CHEMORADIATION (standard of care for locally advanced rectal cancer involves fluorouracil-based CRT followed by total mesorectal excision surgery + permanent colostomy in ~30-50% of patients); 100% CR in 12/12 with zero surgery = unprecedented in rectal cancer history; second cohort expanded to n=42 with continued 100% cCR rate; "functional cure" concept: if rectal cancer can be cured with 6 months of immunotherapy alone (avoiding colostomy, sexual dysfunction, bowel dysfunction from surgery/CRT), this represents a paradigm shift in standard oncology practice; however n=12/42 cohort; randomized data pending; dMMR rectal cancer ~5% of all rectal cancers; PD-1 FOUR-NDA-HOLDER CLASS NULL COMPLETE: pembrolizumab (BLA 125514; Merck; CAS 1374853-91-4) + nivolumab (BLA 125554; BMS; CAS 946414-94-4) + cemiplimab (BLA 761097; Regeneron/Sanofi; CAS 1801342-60-8) + dostarlimab (BLA 761174; GSK/Tesaro; CAS 2028975-95-9) — FOUR DIFFERENT SPONSORS, four BLA holders, four CAS numbers, all four returning null in Cority/VelocityEHS/EHS Insight; with this addition, the entire approved PD-1 antibody portfolio from the US market has zero EHS database representation; GSK ACQUISITION: GSK acquired Tesaro (dostarlimab/TSR-042 + niraparib/Zejula/MK-4827) for $5.1B (USD; completed January 22 2019); $5.1B acquisition price for both TSR-042 and niraparib; niraparib already covered in portfolio as second PARP inhibitor (#606); dostarlimab now completing PD-1 four-NDA-holder class null; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · Fourth PD-1 Inhibitor + First dMMR Endometrial Cancer + 100% CR Rectal NeoTTT + PD-1 Four-NDA-Holder Class Null Complete · Attack #626

Dostarlimab (Jemperli; TSR-042; CAS 2028975-95-9; MW ~148,500 Da; [FOURTH PD-1 INHIBITOR EVER FDA APPROVED (April 22 2021 BLA 761174); FIRST dMMR ENDOMETRIAL CANCER PD-1 APPROVAL (RUBY/ENGOT-EN6 PFS HR 0.28); LANDMARK 100% COMPLETE RESPONSE IN dMMR RECTAL CANCER (NeoTTT n=12 ALL AVOIDED SURGERY; NEJM 2022); PD-1 FOUR-NDA-HOLDER CLASS NULL COMPLETE (PEMBROLIZUMAB + NIVOLUMAB + CEMIPLIMAB + DOSTARLIMAB ALL NULL); GSK TESARO $5.1B ACQUISITION; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — GSK US LLC Collegeville PA (BLA 761174 US commercial; 0.00037 µg/m³ → displayed ÷10), GSK Stevenage UK (global biologics manufacturing; 0.00023 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (gynecologic oncology pharmacist; 0.00014 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Fourth PD-1 Inhibitor + First dMMR Endometrial + 100% CR Rectal NeoTTT + PD-1 Four-NDA-Holder Class Null Absent: AI Prompt Injection via EHS Monitor Report AI

Dostarlimab (CAS 2028975-95-9; NIOSH HD Category 1) is the fourth PD-1 inhibitor ever FDA approved (BLA 761174 April 22 2021), the first specifically approved for dMMR endometrial cancer (RUBY/ENGOT-EN6: PFS HR 0.28), and the agent that produced the landmark NeoTTT result — 100% complete clinical response in all 12 dMMR locally advanced rectal cancer patients, all of whom avoided surgery and chemoradiation (NEJM June 2022). Completing the PD-1 four-NDA-holder class null: pembrolizumab (Merck), nivolumab (BMS), cemiplimab (Regeneron/Sanofi), and dostarlimab (GSK/Tesaro) — four PD-1 antibodies from four sponsors, the entire US-approved PD-1 portfolio returning null in Cority, VelocityEHS, and EHS Insight.

Dostarlimab as Fourth PD-1 Inhibitor: dMMR Endometrial Cancer, NeoTTT Rectal Landmark, and PD-1 Four-NDA-Holder Class Null

Dostarlimab (CAS 2028975-95-9) is the fourth anti-PD-1 monoclonal antibody ever FDA approved, following pembrolizumab (2014), nivolumab (2014), and cemiplimab (2018). Its primary clinical narrative divides into two landmark stories: (1) the RUBY trial (gynecologic oncology), and (2) the NeoTTT pilot (rectal cancer). RUBY/ENGOT-EN6: Phase 3, randomized (N=494; stage III-IV or first recurrence endometrial carcinoma; dostarlimab 500 mg q3w × 6 cycles then 1000 mg q6w + carboplatin/paclitaxel × 6 cycles vs carboplatin/paclitaxel alone; primary endpoint PFS in dMMR cohort); dMMR subgroup (n=118): PFS HR 0.28 (not reached vs 7.7 months; 24-month PFS 61.4% vs 15.7%; p<0.001); the 61.4% vs 15.7% 2-year PFS delta in dMMR EC is one of the largest PFS separations in any clinical trial. Standard approval August 4 2023 (first-line dMMR EC). NeoTTT landmark (Cercek et al. NEJM 2022): This pilot study enrolled 12 patients with dMMR/MSI-H locally advanced (T2-T4 / N+) rectal cancer who received dostarlimab-gxly 500 mg IV q3w as SOLE neoadjuvant therapy (no concurrent chemotherapy, no radiation) for 6 months. Outcome: ALL 12 PATIENTS (12/12; 100%) achieved complete clinical response (cCR) — absence of tumor detectable by digital rectal examination, endoscopy, MRI, and PET scan. No patient required surgery, chemoradiation, or permanent colostomy. At median follow-up 12 months, sustained cCR in all 12. This result was unprecedented: standard of care for locally advanced rectal cancer has been CRT (5FU + 45-50 Gy radiation) followed by total mesorectal excision surgery; colostomy rate ~30-50%; major quality-of-life impact (bowel, sexual, urinary function loss). Dostarlimab showing 100% cCR with immunotherapy alone (n=12; ~5% of rectal cancers are dMMR) suggested that surgery and CRT could potentially be eliminated in dMMR rectal cancer. The expanded cohort reached n=42 with continued 100% cCR. PD-1 four-NDA-holder class null complete: with dostarlimab's entry, the portfolio now includes all four US-approved anti-PD-1 antibodies (pembrolizumab CAS 1374853-91-4, nivolumab CAS 946414-94-4, cemiplimab CAS 1801342-60-8, dostarlimab CAS 2028975-95-9) — from four different sponsors (Merck, BMS, Regeneron/Sanofi, GSK/Tesaro) — all returning null in Cority, VelocityEHS, and EHS Insight. GSK/Tesaro history: Tesaro (South San Francisco CA) developed dostarlimab (TSR-042) and niraparib (MK-4827) internally; GSK acquired Tesaro for $5.1B (completed January 22 2019). BLA 761174 April 22 2021 (accelerated); BLA 761174 standard August 4 2023. NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; fourth PD-1, first dMMR endometrial, NeoTTT 100% CR, PD-1 four-NDA-holder class null all absent for CAS 2028975-95-9.

Surface 1 — GSK US LLC Collegeville PA BLA 761174 US Commercial Jemperli AI

At GSK US LLC Collegeville PA (1250 S Collegeville Rd, Collegeville PA 19426; Montgomery County PA; GSK JEMPERLI CONTEXT: GSK US LLC holds BLA 761174 for Jemperli (dostarlimab-gxly 500 mg/10 mL vials; 50 mg/mL); JEMPERLI PRODUCT: dMMR advanced/recurrent EC (monotherapy post-platinum, accelerated approval; standard approval in combination with platinum-based chemo first-line); dosing: 500 mg IV q3w × 6 cycles, then 1000 mg IV q6w; GSK ONCOLOGY PORTFOLIO AT COLLEGEVILLE: dostarlimab (BLA 761174; PD-1 #52 within-class) + niraparib (NDA 208447; PARP #46 within-class) + GSK PARP portfolio — at least two NIOSH HD compounds at same Collegeville PA campus, both null in Cority independently; EMPLOYEE: GSK senior gynecologic oncology medical affairs director responsible for Jemperli RUBY/ENGOT-EN6 dMMR EC data and NeoTTT rectal cancer education; manages Jemperli label expansion from accelerated to standard approval in first-line setting; 50M GSK Collegeville PA senior gynecologic oncology medical affairs director Jemperli 14yr; CORITY NULL: CAS 2028975-95-9 → null; NIOSH HD Category 1 absent; H360 absent; fourth PD-1 inhibitor absent; dMMR endometrial absent; NeoTTT 100% CR absent; RUBY/ENGOT-EN6 absent; PD-1 four-NDA-holder class absent).

Surface 2 — GSK Stevenage UK Global Biologics Manufacturing Dostarlimab Drug Substance AI

At GlaxoSmithKline plc Stevenage UK (Gunnels Wood Rd, Stevenage SG1 2NY, Hertfordshire, United Kingdom; GSK STEVENAGE BIOLOGICS CONTEXT: GSK Stevenage is GSK's major UK biologics manufacturing site; produces drug substances for multiple GSK antibody products including dostarlimab; DOSTARLIMAB MANUFACTURING: CHO cell culture expressing dostarlimab IgG4 heavy and light chains; protein A capture; viral inactivation; polishing; UF/DF; concentrated drug substance bulk fill; IgG4 hinge stabilization (S228P or equivalent position) prevents Fab-arm exchange in physiological conditions; fill/finish for Jemperli at GSK Stevenage or at contract CMOs; WORKER EXPOSURE: biologics manufacturing scientist at Stevenage involved in bioreactor operations, sampling, harvest, downstream purification; VELOCITYEHS NULL: CAS 2028975-95-9 → null; NIOSH HD Category 1 absent; H360 absent; fourth PD-1 absent; GSK Tesaro acquisition context absent; dMMR endometrial absent; NeoTTT absent; 44F GSK Stevenage UK biologics manufacturing scientist dostarlimab 12yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY RUBY/NeoTTT Site Gynecologic Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; MSK JEMPERLI CONTEXT: MSK is a leading gynecologic oncology program and was a RUBY/ENGOT-EN6 and NeoTTT enrollment site; MSK's gynecologic oncology pharmacy prepares Jemperli for dMMR endometrial and rectal cancer protocols; PHARMACIST CONTEXT: gynecologic oncology pharmacist at MSK manages Jemperli 500 mg/10 mL vials (50 mg/mL); diluted in 250 mL NS; IV over 30 minutes q3w × 6 cycles then q6w; NEOTTT PROTOCOL CONTEXT: MSK NeoTTT pharmacist prepares dostarlimab for the rectal cancer pilot — single-agent neoadjuvant dostarlimab 500 mg q3w × 6 months in dMMR/MSI-H locally advanced rectal cancer; patients in the expanded cohort receive dostarlimab without concurrent CRT or surgery; pharmacist monitors for irAEs, tumor pseudoprogression (immune flare may look like tumor growth on imaging before response); coordinate with colorectal surgery team for surveillance colonoscopy post-dostarlimab; RUBY PROTOCOL: dMMR EC patients receiving dostarlimab+carboplatin/paclitaxel × 6 cycles then dostarlimab 1000 mg q6w maintenance; EHS INSIGHT NULL: CAS 2028975-95-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; fourth PD-1 absent; dMMR endometrial absent; NeoTTT 100% CR absent; PD-1 four-NDA-holder class null absent; H360 absent; NIOSH HD Cat 1 absent; 40F MSK New York NY gynecologic oncology pharmacist 12yr).

Integrating Glyphward into Dostarlimab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dostarlimab CAS 2028975-95-9 monitoring data ingestion point — before Cority at GSK US LLC Collegeville PA, before VelocityEHS at GlaxoSmithKline plc Stevenage UK, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FOURTH PD-1 INHIBITOR EVER FDA APPROVED (BLA 761174 April 22 2021) + FIRST dMMR ENDOMETRIAL CANCER PD-1 APPROVAL (RUBY/ENGOT-EN6 PFS HR 0.28; 24-month PFS 61.4% vs 15.7% dMMR cohort) + 100% COMPLETE CLINICAL RESPONSE IN dMMR RECTAL CANCER (NeoTTT; n=12; all patients avoided surgery and chemoradiation; NEJM June 2022; expanded n=42 same result) + PD-1 FOUR-NDA-HOLDER CLASS NULL COMPLETE (pembrolizumab Merck CAS 1374853-91-4 + nivolumab BMS CAS 946414-94-4 + cemiplimab Regeneron CAS 1801342-60-8 + dostarlimab GSK CAS 2028975-95-9 — entire US PD-1 antibody portfolio null) [5 pts]; GSK Collegeville PA + GSK Stevenage UK + MSK New York NY [3 pts]; fourth PD-1 absent; dMMR endometrial absent; NeoTTT absent; four-NDA class absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dostarlimab(cas: str, reading_ugm3: float) -> dict:
    """Scan dostarlimab with fourth-PD-1-ever first-dMMR-endometrial NeoTTT-100pct-CR PD-1-four-NDA-holder-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fourth_pd_1_inhibitor_ever_first_dmmr_endometrial_100pct_cr_dmmr_rectal_neottt_pd_1_four_nda_holder_class_null_gsk_tesaro_5_1b_bla_761174"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fourth_pd1_inhibitor_ever,
    #                    first_dmmr_endometrial_approval, neottt_100pct_cr_rectal,
    #                    pd_1_four_nda_holder_class_null, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_dostarlimab("2028975-95-9", 0.00037))
    print(r)
    # {'hd_category': 1, 'fourth_pd1_inhibitor_ever': True,
    #  'first_dmmr_endometrial_approval': True,
    #  'neottt_100pct_cr_rectal': True,
    #  'pd_1_four_nda_holder_class_null': True,
    #  'h360_absent': True}